Andrx, Amphastar Pen Deal For Generic Lovenox

Law360, New York (May 5, 2005, 12:00 AM EDT) -- Drug maker Andrx Corp. has entered into a marketing rights agreement with Amphastar Pharmaceuticals for a generic version of Sanofi-Aventis’ Lovenox, a treatment for deep vein thrombosis.

Amphastar's generic version is currently the subject of a patent infringement lawsuit brought by Aventis and is under a 30-month stay that expires in February 2006.

In December, Aventis’ bid for a reissuance of the U.S. patent for best-selling anti-blood clotting drug Lovenox finally won approval from the U.S. Patent and Trademark office.

The USPTO previously rejected two attempts...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.